Here are some of the major companies whose stocks moved on the week’s news.

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...

A California physician accused of gross negligence for attributing a stroke patient's death to the COVID vaccine without any ...

We regret to report that long term Pfizer Inc. (NYSE:PFE) shareholders have had that experience, with the share price ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

There are a couple of valuation factors supporting the idea that Pfizer's stock is undervalued, starting with its ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Activist investor Starboard Value accused Pfizer of pressuring its former CEO Ian Read and ex-CFO Frank D’Amelio to halt ...

Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine ...

In this age of over-consumption, ironically capitalism is a hated word, as are the capitalists. In these excerpts, John Kay ...